ALPS Advisors’s Fulcrum Therapeutics FULC Stock Holding History

ALPS Advisors’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Buy	+67,632	New	+$411K	﹤0.01%	1131
2024 Q4	–	Sell	-123,009	Closed	-$439K	–	1008
2024 Q3	$439K	Buy	123,009 +74,530	+154%	+$553K	﹤0.01%	628
2024 Q2	$301K	Buy	48,479 +4,797	+11%	+$36.3K	﹤0.01%	847
2024 Q1	$412K	Buy	43,682 +3,828	+10%	+$34.2K	﹤0.01%	620
2023 Q4	$269K	Buy	+39,854	New	+$177K	﹤0.01%	909
2023 Q2	–	Sell	-40,692	Closed	-$116K	–	1014
2023 Q1	$116K	Buy	40,692 +5,334	+15%	+$47.8K	﹤0.01%	997
2022 Q4	$257K	Buy	+35,358	New	+$231K	﹤0.01%	951

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ALPS Advisors's FULC Position: Q2 2026 in Review

ALPS Advisors opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 67,632 shares worth $248K. The stake represents ﹤0.01% of the portfolio and ranks #1131 among its holdings. This is a return to the name: ALPS Advisors previously reported a position in FULC as recently as Q3 2024.

ALPS Advisors first reported a position in FULC in Q4 2022 and has held it in 7 quarters since. The position peaked at $439K in Q3 2024. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

ALPS Advisors held 67,632 shares of Fulcrum Therapeutics worth $248K as of Q2 2026.
Fulcrum Therapeutics was a new ALPS Advisors position in Q2 2026.
Fulcrum Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1131 holding.
ALPS Advisors first reported a position in Fulcrum Therapeutics in Q4 2022 and has held it in 7 quarters since.
ALPS Advisors's Fulcrum Therapeutics position peaked at $439K in Q3 2024.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.